Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors
Andrea M Chambers,
Kyle B Lupo,
Jiao Wang,
Jingming Cao,
Sagar Utturkar,
Nadia Lanman,
Victor Bernal-Crespo,
Shadia Jalal,
Sharon R Pine,
Sandra Torregrosa-Allen,
Bennett D Elzey,
Sandro Matosevic
Affiliations
Andrea M Chambers
Department of Industrial and Physical Pharmacy, Purdue University West Lafayette, West Lafayette, United States
Kyle B Lupo
Department of Industrial and Physical Pharmacy, Purdue University West Lafayette, West Lafayette, United States
Jiao Wang
Department of Industrial and Physical Pharmacy, Purdue University West Lafayette, West Lafayette, United States
Jingming Cao
Department of Industrial and Physical Pharmacy, Purdue University West Lafayette, West Lafayette, United States
Sagar Utturkar
Center for Cancer Research, Purdue University West Lafayette, West Lafayette, United States
Nadia Lanman
Center for Cancer Research, Purdue University West Lafayette, West Lafayette, United States; Department of Comparative Pathobiology, Purdue University, West Lafayette, United States
Victor Bernal-Crespo
Histology Research Laboratory, Center for Comparative Translational Research, College of Veterinary Medicine, Purdue University, West Lafayette, United States
Shadia Jalal
Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, United States
Sharon R Pine
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States; Department of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, United States; Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, United States
Sandra Torregrosa-Allen
Center for Cancer Research, Purdue University West Lafayette, West Lafayette, United States
Bennett D Elzey
Center for Cancer Research, Purdue University West Lafayette, West Lafayette, United States
Department of Industrial and Physical Pharmacy, Purdue University West Lafayette, West Lafayette, United States; Center for Cancer Research, Purdue University West Lafayette, West Lafayette, United States
Immunometabolic reprogramming due to adenosine produced by CD73 (encoded by the 5’-ectonucleotidase gene NT5E) is a recognized immunosuppressive mechanism contributing to immune evasion in solid tumors. Adenosine is not only known to contribute to tumor progression, but it has specific roles in driving dysfunction of immune cells, including natural killer (NK) cells. Here, we engineered human NK cells to directly target the CD73-adenosine axis by blocking the enzymatic activity of CD73. In doing so, the engineered NK cells not only impaired adenosinergic metabolism driven by the hypoxic uptake of ATP by cancer cells in a model of non-small-cell lung cancer, but also mediated killing of tumor cells due to the specific recognition of overexpressed CD73. This resulted in a ‘single agent’ immunotherapy that combines antibody specificity, blockade of purinergic signaling, and killing of targets mediated by NK cells. We also showed that CD73-targeted NK cells are potent in vivo and result in tumor arrest, while promoting NK cell infiltration into CD73+ tumors and enhancing intratumoral activation.